

Japanese electronics company Ricoh enters into CRISPR/Cas9 license agreement with ERS Genomics

13 March 2024 | News

CRISPR/Cas9 genome editing technology contributes to the expansion of the creation of novel disease model



Ricoh Company has announced a non-exclusive licensing agreement in the US and Japan, with Ireland-headquartered ERS Genomics for access to the foundational CRISPR/Cas9 genome editing technology patents managed by ERS Genomics.

CRISPR/Cas9 stands as a breakthrough gene editing technology, enabling modification of targeted genome sequences with ease. The technology is an essential tool in drug discovery research and finds application across various fields.

In 2022, Ricoh completed the acquisition of US-based Elixirgen Scientific, Inc. which possesses core technologies in rapid and efficient differentiation of human iPS cells, and mRNA design, production, and management.

Ricoh has been expanding the application areas of Elixirgen Scientific's technology by leveraging cultivated expertise in digital and artificial intelligence technologies. This initiative aims to accelerate personalised medicine, drug discovery research and regenerative medicine.

Summit Pharmaceuticals International Corporation, a subsidiary of Sumitomo Corporation, is the exclusive representative of ERS Genomics in Japan.